OR WAIT null SECS
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
This final article in the series has two purposes: to summarize all the considerations that go into a company’s compendial affairs program and to look ahead at topics that will likely result in further evolution in the pharmacopoeias around the world.